Medtronic plc (VIE:MDT)
Austria
· Delayed Price · Currency is EUR 88.00
+0.30 (0.34%)
At close: Dec 5, 2025
Revenue
Fiscal year is May - April.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2014 - 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '25 Oct 24, 2025 | Apr '25 Apr 25, 2025 | Apr '24 Apr 26, 2024 | Apr '23 Apr 28, 2023 | Apr '22 Apr 29, 2022 | 2014 - 2021 |
| Cardiac Rhythm & Heart Failure Revenue | 6.82B | 6.39B |
Log In |
Log In |
Log In | Upgrade
|
| Structural Heart & Aortic Revenue | 3.70B | 3.55B |
Log In |
Log In |
Log In | Upgrade
|
| Coronary & Peripheral Vascular Revenue | 2.58B | 2.54B |
Log In |
Log In |
Log In | Upgrade
|
| Cardiovascular Revenue | 13.09B | 12.48B |
Log In |
Log In |
Log In | Upgrade
|
| Cranial & Spinal Technologies Revenue | 5.10B | 4.97B |
Log In |
Log In |
Log In | Upgrade
|
| Specialty Therapies Revenue | 2.94B | 2.94B |
Log In |
Log In |
Log In | Upgrade
|
| Neuromodulation Revenue | 2.02B | 1.93B |
Log In |
Log In |
Log In | Upgrade
|
| Neuroscience Revenue | 10.06B | 9.85B |
Log In |
Log In |
Log In | Upgrade
|
| Surgical & Endoscopy Revenue | 6.60B | 6.50B |
Log In |
Log In |
Log In | Upgrade
|
| Acute Care & Monitoring Revenue | 1.94B | 1.91B |
Log In |
Log In |
Log In | Upgrade
|
| Medical Surgical Revenue | 8.54B | 8.41B |
Log In |
Log In |
Log In | Upgrade
|
| Diabetes Revenue | 2.90B | 2.76B |
Log In |
Log In |
Log In | Upgrade
|
| Other Segment Revenue | 170.00M | 137.00M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | - | -89.00M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 34.76B | 33.54B |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is May - April.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2014 - 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '25 Oct 24, 2025 | Apr '25 Apr 25, 2025 | Apr '24 Apr 26, 2024 | Apr '23 Apr 28, 2023 | Apr '22 Apr 29, 2022 | 2014 - 2021 |
| U.S. Revenue | 17.52B | 17.17B |
Log In |
Log In |
Log In | Upgrade
|
| Non-U.S. Developed Markets Revenue | - | 10.20B |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets Revenue | - | 6.20B |
Log In |
Log In |
Log In | Upgrade
|
| Total International Revenue | 17.23B | 16.37B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | - | 1.00M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 34.76B | 33.54B |
Log In |
Log In |
Log In | Upgrade
|
EBIT
Fiscal year is May - April.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2014 - 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '25 Oct 24, 2025 | Apr '25 Apr 25, 2025 | Apr '24 Apr 26, 2024 | Apr '23 Apr 28, 2023 | Apr '22 Apr 29, 2022 | 2014 - 2021 |
| Cardiovascular Operating Profit | 4.22B | 4.80B |
Log In |
Log In |
Log In | Upgrade
|
| Neuroscience Operating Profit | 3.64B | 4.18B |
Log In |
Log In |
Log In | Upgrade
|
| Medical Surgical Operating Profit | 2.60B | 3.04B |
Log In |
Log In |
Log In | Upgrade
|
| Diabetes Operating Profit | 352.00M | 491.00M |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Other) | -4.60B | -6.56B |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Total) | 6.21B | 5.96B |
Log In |
Log In |
Log In | Upgrade
|
Key Performance Indicators
Fiscal year is May - April.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2013 - 2020 |
|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 25, 2025 | Apr '24 Apr 26, 2024 | Apr '23 Apr 28, 2023 | Apr '22 Apr 29, 2022 | 2013 - 2020 |
| Cardiovascular Organic Revenue Growth | 6.30% |
Log In |
Log In |
Log In | Upgrade
|
| Neuroscience Organic Revenue Growth | 5.20% |
Log In |
Log In |
Log In | Upgrade
|
| Medical Surgical Organic Revenue Growth | 0.80% |
Log In |
Log In |
Log In | Upgrade
|
| Diabetes Organic Revenue Growth | 11.50% |
Log In |
Log In |
Log In | Upgrade
|
| Total Organic Revenue Growth | 4.90% |
Log In |
Log In |
Log In | Upgrade
|